Targeted immunotherapy of cancer with CAR T cells: Achievements and challenges

Grazyna Lipowska-Bhalla, David E. Gilham, Robert E. Hawkins, Dominic G. Rothwell

Research output: Contribution to journalArticlepeer-review


The adoptive transfer of chimeric antigen receptor (CAR)-expressing T cells is a relatively new but promising approach in the field of cancer immunotherapy. This therapeutic strategy is based on the genetic reprogramming of T cells with an artificial immune receptor that redirects them against targets on malignant cells and enables their destruction by exerting T cell effector functions. There has been an explosion of interest in the use of CAR T cells as an immunotherapy for cancer. In the pre-clinical setting, there has been a considerable focus upon optimizing the structural and signaling potency of the CAR while advances in bio-processing technology now mean that the clinical testing of these gene-modified T cells has become a reality. This review will summarize the concept of CAR-based immunotherapy and recent clinical trial activity and will further discuss some of the likely future challenges facing CAR-modified T cell therapies. © 2012 Springer-Verlag.
Original languageEnglish
Pages (from-to)953-962
Number of pages9
JournalCancer Immunology, Immunotherapy
Issue number7
Publication statusPublished - Jul 2012


  • Cancer
  • Chimeric antigen receptor
  • Gene modification
  • Immunotherapy
  • T cell


Dive into the research topics of 'Targeted immunotherapy of cancer with CAR T cells: Achievements and challenges'. Together they form a unique fingerprint.

Cite this